Global Narcolepsy Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2031

졸음증 치료 시장 분석

졸음증 치료 시장은 졸음증 유병률 증가와 치료 옵션의 발전으로 상당한 성장을 목격하고 있습니다. 오렉신 수용체 길항제와 같은 새로운 치료법은 졸음증 병태생리학의 기저 경로를 표적으로 삼아 치료적 접근 방식을 개선하고 있습니다. 최근 Avadel과 Jazz Pharmaceuticals와 같은 회사는 졸음증 증상을 보다 효과적으로 관리하는 데 유망한 결과를 보이는 혁신적인 약물로 주목을 받고 있습니다. 시장 확장은 수면 장애에 대한 인식 증가와 더 나은 진단율로도 뒷받침됩니다. 신경 치료제의 R&D 와 원격 진료의 발전으로 진단과 치료 접근성이 개선되어 환자에게 도움이 되고 시장 역학을 지원함에 따라 성장이 지속될 것으로 예상됩니다.

졸음증 치료 시장 규모

글로벌 졸음증 치료 시장 규모는 2023년에 31억 5천만 달러로 평가되었으며, 2031년까지 70억 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 10.50%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

졸음증 치료 시장 동향

“ 약리학적 치료의 발전”

졸음증 치료 시장은 과도한 주간 졸음증과 기면증을 관리하는 데 있어 환자 치료를 개선하고 충족되지 않은 요구 사항을 해결하기 위한 혁신에 중점을 두고 진화하고 있습니다. 약물 치료의 발전이 성장을 주도하고 있으며, 오렉신 수용체 길항제를 포함한 새로운 계열의 약물이 졸음증의 근본 원인을 효과적으로 타겟팅하는 잠재력을 보여주고 있습니다. 시장에서 주목할 만한 추세는 투약 빈도를 줄이고 환자의 준수와 삶의 질을 개선하는 장기 작용 약물의 개발입니다. 원격 의료와 웨어러블 건강 기술의 혁신은 수면 장애를 보다 효율적으로 모니터링하여 치료를 보다 쉽게 ​​접근할 수 있도록 돕고 있습니다. 인지도가 높아지고 진단율이 향상됨에 따라 시장은 졸음증에 대한 효과적이고 개인화된 치료 옵션을 보다 광범위하게 제공할 준비가 되었습니다.

보고서 범위 및 졸음증 치료 시장 세분화       

졸음증 치료 시장 정의

기면증 치료에는 과도한 주간 졸음증, 갑작스러운 수면 장애, 때로는 기면증(감정에 의해 갑작스럽게 근긴장도가 떨어지는 증상) 등이 특징인 만성 신경 질환인 기면증의 증상을 관리하기 위해 고안된 의학적 전략과 개입이 포함됩니다. 약물 치료(각성제, 항우울제 등)와 생활 습관 개선, 행동 전략을 병행하여 수면의 질과 일상 생활을 개선합니다.

졸음증 치료 시장 동향

운전자

• 기면증 발병률 증가

The rising incidence of narcolepsy is a significant driver of the treatment market. As awareness of this condition increases among both healthcare professionals and the general public, more individuals are being diagnosed and seeking effective management options. This heightened awareness facilitates earlier diagnosis and encourages individuals to pursue treatment, leading to an increased demand for targeted therapies. Consequently, pharmaceutical companies are motivated to develop innovative treatment solutions to address the growing patient population, ultimately driving market growth.

• Advancements in Selective Histamine H3-Receptor Antagonists

The development in the field of narcolepsy treatment have resulted in the emergence of new and innovative therapies that significantly enhance patient care. The introduction of selective histamine H3-receptor antagonists and novel stimulant medications exemplifies this progress, offering improved symptom management for individuals affected by narcolepsy. These advancements provide more effective treatment options and cater to diverse patient needs, enabling tailored approaches to symptom control. As healthcare providers gain access to these cutting-edge treatments, the overall demand for narcolepsy therapies is expected to rise, driving market growth and improving the quality of life for patients.

Opportunities

• Integration of New Drug Classes

The emergence of new drug classes, particularly orexin receptor antagonists and gene therapies, presents significant opportunities in the narcolepsy treatment market. Orexin receptor antagonists target the underlying mechanisms of narcolepsy, providing a novel approach to managing symptoms and improving sleep quality. Additionally, gene therapies aim to address the genetic factors contributing to the disorder, offering the potential for long-term solutions. These advancements can fill existing gaps in treatment options, enhance patient outcomes, and attract attention from pharmaceutical companies seeking to innovate in a market that is increasingly focused on personalized medicine and effective symptom management.

• Rising Integration of Wearable Devices

The integration of wearable devices and mobile applications into the narcolepsy treatment landscape offers substantial market opportunities by enhancing patient engagement and improving treatment outcomes. These technologies allow for real-time monitoring of symptoms, enabling patients to track their sleep patterns, alertness levels, and medication adherence. With data readily available, healthcare providers can make informed decisions and tailor treatment plans to individual needs. Additionally, increased patient engagement through these platforms fosters a proactive approach to managing narcolepsy, ultimately leading to better adherence to prescribed therapies and improved quality of life. This trend reflects the growing emphasis on digital health solutions in modern healthcare.

Restraints/Challenges

• Limited Treatment Options

Despite the availability of various treatments for narcolepsy, options can remain limited, especially for patients experiencing specific symptoms or those with comorbid conditions. For instance, individuals who also suffer from psychiatric disorders or sleep apnea may not respond effectively to standard treatments, highlighting the need for tailored therapeutic approaches. This limitation necessitates ongoing research and development of diverse therapies that can cater to a broader range of symptoms and patient profiles. The lack of comprehensive treatment options can hinder effective symptom management and overall patient satisfaction, ultimately posing a challenge for healthcare providers and the narcolepsy treatment market.

•  High Cost of Narcolepsy Medications

The high cost of many narcolepsy treatment medications presents a significant barrier to patient access and adherence to treatment regimens. For individuals without sufficient insurance coverage, the financial burden can be overwhelming, leading to delays in seeking necessary medical care. This situation may force patients to make difficult choices between essential medications and other living expenses. Consequently, limited access to effective treatments can adversely affect overall patient outcomes, leading to increased morbidity associated with narcolepsy symptoms. As a result, the financial implications of narcolepsy treatments serve as a critical restraint on market growth, emphasizing the need for more affordable therapeutic options.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Narcolepsy Treatment Market Scope

The market is segmented on the basis of type, drugs, route of administration, end-users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Type 1 Narcolepsy
• Type 2 Narcolepsy

Drugs

• Selective Histamine H3-Receptor Antagonist
• Stimulants
• Serotonin Reuptake Inhibitors
• Tricyclic Antidepressants
• Central Nervous System Depressant
• Others

Route of Administration

• Oral
• Injectable

End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

 Narcolepsy Treatment Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, type, drugs, route of administration, end-users, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the narcolepsy treatment market, driven by escalating healthcare expenditures and a robust focus on research and development. The region's commitment to innovation and the adoption of advanced technologies further enhance its market position. These factors collectively contribute to the region's dominance in providing effective narcolepsy treatments.

Asia-Pacific region is projected to experience the highest growth rate from 2024 to 2031, fueled by strategic initiatives implemented by key market players. Additionally, supportive government policies aimed at enhancing healthcare access and innovation play a crucial role in this growth. Together, these factors are expected to significantly drive the narcolepsy treatment market in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Narcolepsy Treatment Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Narcolepsy Treatment Market Leaders Operating in the Market Are:

• Avadel (Ireland)
• Vallon Pharmaceuticals (U.S.)
• Jazz Pharmaceuticals, Inc. (Ireland)
• Jubilant Pharmova Limited (India)
• BIOPROJET (France)
• Hikma Pharmaceuticals PLC (U.K.)
• Amneal Pharmaceuticals LLC (U.S.)
• Teva Pharmaceutical Industries Ltd (Ireland)
• Ligand Pharmaceuticals Incorporated (U.S.)
• Novartis AG (Switzerland)
• Viatris Inc. (U.S.)
• Alkem (India)
• Alembic Pharmaceuticals Limited (India)
• Torrent Pharmaceuticals Ltd (India)
• Johnson & Johnson Private Limited (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Zydus Group (India)

Latest Developments in Narcolepsy Treatment Market

• In March 2022, Jazz Pharmaceuticals announced a definitive agreement to acquire Sunosi (solriamfetol), a medication used to treat excessive daytime sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA). The acquisition is expected to close in the second quarter of 2022. This strategic move aims to enhance Jazz's portfolio of treatments for sleep disorders
• In February 2022, Takeda Pharmaceutical Company Limited announced the submission of a New Drug Application (NDA) for TAK-998, also referred to as Wakixol, to the U.S. Food and Drug Administration (FDA). This innovative oral medication functions as a dopamine and norepinephrine reuptake inhibitor (DNRI) and is designed specifically to treat cataplexy in adult patients diagnosed with narcolepsy. The filing represents a significant step forward in Takeda's commitment to addressing the needs of those affected by narcolepsy
• In January 2022, Harmony Biosciences LLC announced the initiation of a Phase 3 clinical trial for pitolisant, a histamine H3 receptor antagonist. This trial aims to evaluate the efficacy of pitolisant in treating adults with narcolepsy experiencing excessive daytime sleepiness (EDS). The study represents a significant advancement in developing targeted therapies for individuals suffering from this debilitating symptom of narcolepsy
• In January 2020, Axsome Therapeutics, Inc., a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, secured an exclusive U.S. license from Pfizer Inc. This agreement grants Axsome access to Pfizer’s clinical and nonclinical data, as well as the intellectual property related to reboxetine, the active pharmaceutical ingredient in AXS-12, which is being developed for narcolepsy treatment. This collaboration is expected to enhance Axsome's capabilities in advancing AXS-12's development   

SKU-47800